William Antebi
About William Antebi
William Antebi is the Director of FP&A at KalVista Pharmaceuticals, Inc., with extensive experience in finance within the pharmaceutical industry. He has held various positions at companies such as Ironwood Pharmaceuticals, Seres Therapeutics, and Takeda, and holds an MBA from Boston University and a BA from the University of Massachusetts Amherst.
Current Role at KalVista Pharmaceuticals
William Antebi serves as the Director of Financial Planning and Analysis (FP&A) at KalVista Pharmaceuticals, Inc. since 2023. In this role, he is responsible for overseeing financial strategies, budgeting, and forecasting to support the company's objectives. His position is based in Cambridge, Massachusetts, where he has been contributing to the organization for 11 months.
Previous Experience in Finance
Prior to his current role, Antebi held various positions in finance within the pharmaceutical sector. He worked at Ironwood Pharmaceuticals as Associate Director of R&D Finance for 7 months in 2020. He also served at Seres Therapeutics, first as Associate Director of Finance from 2020 to 2022, and then as Director of Finance from 2022 to 2023. His earlier experience includes roles at Takeda and MILLENNIUM PHARMACEUTICALS, INC., where he developed expertise in financial modeling and analysis.
Educational Background
William Antebi earned a Master of Business Administration (MBA) from Boston University School of Management, completing his studies from 1997 to 1999. He also holds a Bachelor of Arts (BA) in Comparative Literature with a minor in Physics from the University of Massachusetts Amherst, which he obtained from 1988 to 1992. Additionally, he participated in a study abroad program at the University of Dakar, Senegal, focusing on Economics and Politics.
Expertise in Pharmaceutical Finance
Antebi has extensive experience in the pharmaceutical industry, particularly in financial planning and analysis. He has developed skills in transaction valuation, portfolio analysis, and reporting. With fourteen years of experience in pharmaceutical research and development (R&D) and business development, he has a strong understanding of the financial dynamics within this sector.